Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia

Subjects will be contacted (phone script attached) to inform them of the study and the
imaging modality. The first 10 patients that agree to participate in the study will be asked
to present to the Mayo Clinic where they can provide a written consent and perform the
imaging study.

Enrolled subjects will be evaluated in the clinical practice prior to having 68Ga-DOTATATE
PET/CT imaging performed. The treating endocrinologist will be informed of the imaging
results and will review the results with the subject using a follow-up visit or phone call;
when a tumor is localized, the endocrinologist will discuss appropriate management options.

Subjects will be follow for one year post 68Ga-DOTATATE PET/CT.

Inclusion Criteria:

- Adults (18 years of age or older) seen at Mayo Clinic, Rochester for FGF23 mediated
osteomalacia between 1/1/2000 and 1/30/2018 who provide informed consent to
participate in the study.

Exclusion Criteria:

- Pregnant

- Prisoners

- Subjects diagnosed with heritable hypophosphatemic rickets/osteomalacia

- Subjects who do not consent for the study or withdraw consent during the duration of
the study.

- Subjects in whom tumor localization and successful resection has already occurred.